Published in J Clin Invest on August 01, 2008
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
The pathobiology of splicing. J Pathol (2010) 2.52
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med (2013) 1.53
Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol (2009) 1.33
Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32
KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst (2010) 1.14
Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol (2008) 1.07
Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol (2013) 1.04
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res (2009) 1.00
Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One (2010) 0.99
The molecular biology of brain metastasis. J Oncol (2012) 0.96
Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA (2013) 0.96
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology (2012) 0.94
Krüppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget (2014) 0.90
Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer (2009) 0.89
Animal models and molecular imaging tools to investigate lymph node metastases. J Mol Med (Berl) (2011) 0.87
Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol (2014) 0.87
Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Invest (2015) 0.86
Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer (2008) 0.85
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology (2012) 0.85
Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res (2010) 0.85
Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging (2009) 0.84
Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol (2009) 0.83
Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas. PLoS One (2010) 0.83
KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. Am J Pathol (2012) 0.83
Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett (2010) 0.83
Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology (2012) 0.81
A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer (2011) 0.81
Alternative splicing programs in prostate cancer. Int J Cell Biol (2013) 0.81
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene (2016) 0.79
Inhibition of proliferation of rat lens epithelial cell by overexpression of KLF6. Mol Vis (2011) 0.78
Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med (2009) 0.77
Determination of nuclear localization signal sequences for Krüppel-like factor 8. Methods Mol Biol (2010) 0.76
KLF6 depletion promotes NF-κB signaling in glioblastoma. Oncogene (2017) 0.76
KLF6SV1 siRNA inhibits proliferation of human lens epithelial cells. Mol Vis (2012) 0.75
KLF4α stimulates breast cancer cell proliferation by acting as a KLF4 antagonist. Oncotarget (2016) 0.75
A summary of relationships between alternative splicing and breast cancer. Oncotarget (2017) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer (2003) 2.70
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res (2006) 1.75
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res (2005) 1.65
Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis (2006) 1.64
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59
Molecular profiling of angiogenesis markers. Am J Pathol (2002) 1.57
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57
Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet (2004) 1.54
Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res (2004) 1.52
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today (2006) 1.32
E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene (2006) 1.22
A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene (2004) 1.20
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res (2005) 1.19
Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res (2006) 1.02
Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene (2004) 1.02
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? Eur J Cancer (2005) 1.01
[Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas]. Ai Zheng (2002) 0.99
Management of prostate cancer. Part 2: localized and locally advanced disease. Expert Rev Anticancer Ther (2006) 0.80
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
Pathogenesis of liver fibrosis. Annu Rev Pathol (2011) 5.27
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Integrative analysis of the cancer transcriptome. Nat Genet (2005) 4.44
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Expressed pseudogenes in the transcriptional landscape of human cancers. Cell (2012) 4.22
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Probabilistic model of the human protein-protein interaction network. Nat Biotechnol (2005) 3.99
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92